Xenoport Inc (XNPT) 6.69 $XNPT
Biotech Stock Roundup: Achillion Impresses with HCV Data, Regeneron 4Q Results Top Estimates - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 11, 10:47AM CST
The hepatitis C virus (HCV) market remains in focus with Achillion (ACHN) presenting encouraging data.
GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), ABBV: 58.05 (+1.00), ALKS: 71.40 (-1.89), REGN: 402.40 (+0.66), XNPT: 6.69 (-0.21), CELG: 115.88 (+0.16)
17 Healthcare Companies To Consider Based On Patent Dynamics And IP/Patent Indexes
Innovalpha - Seeking Alpha - Tue Feb 10, 8:08AM CST
Introduction We will present here a few healthcare stocks that have been recently selected by our IP models. As already explained in our SA article " Patent Dynamics And Stock Performance ", Innovalpha has developed proprietary IP and...
SGYP: 2.98 (unch), INSM: 17.40 (+0.69), RNN: 0.75 (+0.01), ZSPH: 46.77 (+3.42), RDHL: 12.69 (+0.04), ASPX: 65.76 (+2.76), ACUR: 0.55 (+0.01), XNPT: 6.69 (-0.21), SPNC: 33.69 (-0.06), CORI: 7.00 (-0.05), SAGE: 41.03 (-0.07), EBIO: 10.13 (+0.05), HAE: 42.94 (-0.59), JAZZ: 169.69 (+6.89), ICPT: 209.12 (+7.12), NVDQ: 15.12 (+0.51)
Commit To Purchase XenoPort At $6, Earn 22.7% Annualized Using Options
at The Street - Thu Feb 05, 11:15AM CST
Investors eyeing a purchase of XenoPort Inc stock, but cautious about paying the going market price of $7.21/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in...
XNPT: 6.69 (-0.21)
XenoPort to Release Fourth Quarter and Year-End Financial Results on February 19, 2015
Business Wire - Thu Feb 05, 9:00AM CST
XenoPort, Inc. (Nasdaq:XNPT) announced today that it will release its fourth quarter and year-end financial results on February 19, 2015 at approximately 4:30 p.m. Eastern Time. The company will host a conference call at 5:00 p.m. Eastern Time that same day to provide a summary of its financial results and general business updates. A replay of the call will be available for one week following the event.
XNPT: 6.69 (-0.21)
Xenoport: Significant Growth Potential On Horizant Sales And A Solid Pipeline
ONeil Trader - at Seeking Alpha - Wed Feb 04, 9:45AM CST
XNPT: 6.69 (-0.21)
Why XenoPort, Inc. Shares Tanked Today
Sean Williams, The Motley Fool - Motley Fool - Tue Feb 03, 2:34PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of XenoPort , a biopharmaceutical company...
XNPT: 6.69 (-0.21)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 11:47AM CST
SD: 2.09 (+0.14), RAVE: 13.57 (+0.28), SPPR: 1.63 (-0.17), PSTI: 2.91 (+0.01), ONTX: 2.27 (-0.02), LMNX: 15.45 (+0.02), NBG: 1.61 (+0.18), ARDX: 17.14 (+0.71), CSIQ: 28.84 (-0.30), LFVN: 1.11 (-0.02), XNPT: 6.69 (-0.21), GBR: 1.48 (-0.10), GENE: 8.04 (+1.90), RCII: 30.49 (+0.92), PWE: 2.45 (+0.02), PSTR: 4.63 (+0.14), SSYS: 67.16 (-0.34), ODP: 9.59 (-0.02), ENRJ: 2.81 (+0.06)
XenoPort Announces Pricing of $100 Million 2.50% Convertible Senior Notes due 2022
Business Wire - Thu Jan 29, 8:02AM CST
XenoPort, Inc. (NASDAQ: XNPT) announced today the pricing of $100 million aggregate principal amount of 2.50% Convertible Senior Notes due 2022 in a private placement to qualified institutional buyers pursuant to Rule 144A (the "offering"
under the Securities Act of 1933, as amended (the "Securities Act" . In connection with the offering, XenoPort also granted the initial purchasers of the notes a 30-day option to purchase up to an additional $15 million aggregate principal amount of the notes to cover over-allotments, if any. The sale of the notes is expected to close on February 3, 2015, subject to customary closing conditions.
XNPT: 6.69 (-0.21)
XenoPort initiates convertible debt offering
Seeking Alpha - at Seeking Alpha - Wed Jan 28, 4:16PM CST
XNPT: 6.69 (-0.21)
XenoPort Announces Proposed Offering of $100 Million Convertible Senior Notes due 2022
Business Wire - Wed Jan 28, 3:36PM CST
XenoPort, Inc. (Nasdaq: XNPT) announced today that it intends to offer, subject to market and other conditions, $100 million aggregate principal amount of convertible senior notes due 2022 in a private placement to qualified institutional buyers pursuant to Rule 144A (the "offering" under the Securities Act of 1933, as amended (the "Securities Act" . In connection with the offering, XenoPort expects to grant the initial purchasers of the notes a 30-day option to purchase up to an additional $15 million aggregate principal amount of the notes from XenoPort to cover over-allotments, if any.
XNPT: 6.69 (-0.21)
Xenoport (XNPT) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 15, 9:01AM CST
Xenoport (XNPT) Shares March Higher, Can It Continue?
XNPT: 6.69 (-0.21)
XenoPort Prepping For Key Data In 2015
Stephen Simpson, CFA - at Seeking Alpha - Wed Jan 14, 4:59PM CST
BIIB: 391.66 (-0.45), FWP: 22.66 (-0.09), ALKS: 71.40 (-1.89), XNPT: 6.69 (-0.21)
A Company's First Profit Can Mean Big Profits to Investors - Screen of the Week
Kevin Matras - Zacks Investment Research - Tue Jan 13, 12:00AM CST
A Company's First Profit Can Mean Big Profits to Investors - Screen of the Week
INCY: 75.94 (+0.28), OPHT: 51.11 (+0.12), AGIO: 118.55 (+0.11), OSUR: 8.13 (+0.06), XNPT: 6.69 (-0.21)
Horizant scripts up 95% from year ago
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 1:44PM CST
XNPT: 6.69 (-0.21)
XenoPort Provides Highlights of HORIZANT Prescription Trends and Update on Development for Alcohol Use Disorder
Business Wire - Sun Jan 11, 12:00PM CST
XenoPort (NASDAQ:XNPT) today reported an update on prescription trends and further development of HORIZANT(R) (gabapentin enacarbil) Extended-Release Tablets, including feedback from the U.S. Food and Drug Administration (FDA) on development for treatment of alcohol use disorder (AUD).
XNPT: 6.69 (-0.21)
XenoPort's Has Upside But Wait For Catalyst
Value Insight - at Seeking Alpha - Tue Jan 06, 9:51AM CST
XNPT: 6.69 (-0.21)
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/2n69ld/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects Scope - The report provides a snapshot of the global therapeutic landscape of Relapsing Remitting Multiple Sclerosis (RRMS) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Relapsing Remitting Multiple Sclerosis (RRMS) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Relapsing Remitting Multiple Sclerosis (RRMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Relapsing Remitting Multiple Sclerosis (RRMS) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - MedImmune, LLC - XenoPort, Inc. - Novartis AG - Actelion Ltd - Mitsubishi Tanabe Pharma Corporation - Octapharma AG - Teva Pharmaceutical Industries Limited - Genmab A/S - Merck KGaA - Antisense Therapeutics Limited - Opexa Therapeutics - Trophos SA - Allozyne - Amarna Therapeutics - Synthetic Biologics - Cognosci - RedHill Biopharm - Nuron Biotech - Neurotec Pharma SL - BIOCAD - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/2n69ld/relapsing
GSK: 47.94 (+1.99), XNPT: 6.69 (-0.21), OPXA: 0.71 (-0.03), SYN: 2.13 (+0.18), ABBV: 58.05 (+1.00), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Xenoport, Inc. (XNPT) in Focus: Stock Jumps 5.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 8:21AM CST
Xenoport, Inc. (XNPT) was a big mover last session, as the company saw its shares rise by over 5% on the day.
AFFX: 11.45 (+0.02), XNPT: 6.69 (-0.21)
Stocks Fall in Light Trading as Oil and Greece Weigh on Markets
at The Street - Tue Dec 30, 3:09PM CST
Oil and Greece were the focus of 2014's penultimate trading session in what was an otherwise quiet day.
GPRO: 45.27 (-0.02), HK: 2.18 (-0.02), ABX: 12.14 (+0.01), AKAM: 68.77 (+1.18), FCX: 20.29 (+0.82), NEM: 24.78 (+0.27), XNPT: 6.69 (-0.21), NDRM: 10.76 (+0.22), RDS.A: 66.32 (+0.97), KGC: 2.81 (-0.17), GLD: 117.98 (+0.64), CVEO: 3.87 (+0.15), BP: 41.93 (+0.59), ARCP: 9.40 (+0.06), YELP: 47.53 (-0.10), XLE: 82.04 (+1.70), GG: 23.54 (+0.23)
Biotech Stock Roundup: Achillion Impresses with HCV Data, Regeneron 4Q Results Top Estimates - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 11, 10:47AM CST
The hepatitis C virus (HCV) market remains in focus with Achillion (ACHN) presenting encouraging data.
GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), ABBV: 58.05 (+1.00), ALKS: 71.40 (-1.89), REGN: 402.40 (+0.66), XNPT: 6.69 (-0.21), CELG: 115.88 (+0.16)
17 Healthcare Companies To Consider Based On Patent Dynamics And IP/Patent Indexes
Innovalpha - Seeking Alpha - Tue Feb 10, 8:08AM CST
Introduction We will present here a few healthcare stocks that have been recently selected by our IP models. As already explained in our SA article " Patent Dynamics And Stock Performance ", Innovalpha has developed proprietary IP and...
SGYP: 2.98 (unch), INSM: 17.40 (+0.69), RNN: 0.75 (+0.01), ZSPH: 46.77 (+3.42), RDHL: 12.69 (+0.04), ASPX: 65.76 (+2.76), ACUR: 0.55 (+0.01), XNPT: 6.69 (-0.21), SPNC: 33.69 (-0.06), CORI: 7.00 (-0.05), SAGE: 41.03 (-0.07), EBIO: 10.13 (+0.05), HAE: 42.94 (-0.59), JAZZ: 169.69 (+6.89), ICPT: 209.12 (+7.12), NVDQ: 15.12 (+0.51)
Commit To Purchase XenoPort At $6, Earn 22.7% Annualized Using Options
at The Street - Thu Feb 05, 11:15AM CST
Investors eyeing a purchase of XenoPort Inc stock, but cautious about paying the going market price of $7.21/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in...
XNPT: 6.69 (-0.21)
XenoPort to Release Fourth Quarter and Year-End Financial Results on February 19, 2015
Business Wire - Thu Feb 05, 9:00AM CST
XenoPort, Inc. (Nasdaq:XNPT) announced today that it will release its fourth quarter and year-end financial results on February 19, 2015 at approximately 4:30 p.m. Eastern Time. The company will host a conference call at 5:00 p.m. Eastern Time that same day to provide a summary of its financial results and general business updates. A replay of the call will be available for one week following the event.
XNPT: 6.69 (-0.21)
Xenoport: Significant Growth Potential On Horizant Sales And A Solid Pipeline
ONeil Trader - at Seeking Alpha - Wed Feb 04, 9:45AM CST
XNPT: 6.69 (-0.21)
Why XenoPort, Inc. Shares Tanked Today
Sean Williams, The Motley Fool - Motley Fool - Tue Feb 03, 2:34PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of XenoPort , a biopharmaceutical company...
XNPT: 6.69 (-0.21)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 11:47AM CST
SD: 2.09 (+0.14), RAVE: 13.57 (+0.28), SPPR: 1.63 (-0.17), PSTI: 2.91 (+0.01), ONTX: 2.27 (-0.02), LMNX: 15.45 (+0.02), NBG: 1.61 (+0.18), ARDX: 17.14 (+0.71), CSIQ: 28.84 (-0.30), LFVN: 1.11 (-0.02), XNPT: 6.69 (-0.21), GBR: 1.48 (-0.10), GENE: 8.04 (+1.90), RCII: 30.49 (+0.92), PWE: 2.45 (+0.02), PSTR: 4.63 (+0.14), SSYS: 67.16 (-0.34), ODP: 9.59 (-0.02), ENRJ: 2.81 (+0.06)
XenoPort Announces Pricing of $100 Million 2.50% Convertible Senior Notes due 2022
Business Wire - Thu Jan 29, 8:02AM CST
XenoPort, Inc. (NASDAQ: XNPT) announced today the pricing of $100 million aggregate principal amount of 2.50% Convertible Senior Notes due 2022 in a private placement to qualified institutional buyers pursuant to Rule 144A (the "offering"
under the Securities Act of 1933, as amended (the "Securities Act" . In connection with the offering, XenoPort also granted the initial purchasers of the notes a 30-day option to purchase up to an additional $15 million aggregate principal amount of the notes to cover over-allotments, if any. The sale of the notes is expected to close on February 3, 2015, subject to customary closing conditions. XNPT: 6.69 (-0.21)
XenoPort initiates convertible debt offering
Seeking Alpha - at Seeking Alpha - Wed Jan 28, 4:16PM CST
XNPT: 6.69 (-0.21)
XenoPort Announces Proposed Offering of $100 Million Convertible Senior Notes due 2022
Business Wire - Wed Jan 28, 3:36PM CST
XenoPort, Inc. (Nasdaq: XNPT) announced today that it intends to offer, subject to market and other conditions, $100 million aggregate principal amount of convertible senior notes due 2022 in a private placement to qualified institutional buyers pursuant to Rule 144A (the "offering"
under the Securities Act of 1933, as amended (the "Securities Act" . In connection with the offering, XenoPort expects to grant the initial purchasers of the notes a 30-day option to purchase up to an additional $15 million aggregate principal amount of the notes from XenoPort to cover over-allotments, if any. XNPT: 6.69 (-0.21)
Xenoport (XNPT) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 15, 9:01AM CST
Xenoport (XNPT) Shares March Higher, Can It Continue?
XNPT: 6.69 (-0.21)
XenoPort Prepping For Key Data In 2015
Stephen Simpson, CFA - at Seeking Alpha - Wed Jan 14, 4:59PM CST
BIIB: 391.66 (-0.45), FWP: 22.66 (-0.09), ALKS: 71.40 (-1.89), XNPT: 6.69 (-0.21)
A Company's First Profit Can Mean Big Profits to Investors - Screen of the Week
Kevin Matras - Zacks Investment Research - Tue Jan 13, 12:00AM CST
A Company's First Profit Can Mean Big Profits to Investors - Screen of the Week
INCY: 75.94 (+0.28), OPHT: 51.11 (+0.12), AGIO: 118.55 (+0.11), OSUR: 8.13 (+0.06), XNPT: 6.69 (-0.21)
Horizant scripts up 95% from year ago
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 1:44PM CST
XNPT: 6.69 (-0.21)
XenoPort Provides Highlights of HORIZANT Prescription Trends and Update on Development for Alcohol Use Disorder
Business Wire - Sun Jan 11, 12:00PM CST
XenoPort (NASDAQ:XNPT) today reported an update on prescription trends and further development of HORIZANT(R) (gabapentin enacarbil) Extended-Release Tablets, including feedback from the U.S. Food and Drug Administration (FDA) on development for treatment of alcohol use disorder (AUD).
XNPT: 6.69 (-0.21)
XenoPort's Has Upside But Wait For Catalyst
Value Insight - at Seeking Alpha - Tue Jan 06, 9:51AM CST
XNPT: 6.69 (-0.21)
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/2n69ld/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects Scope - The report provides a snapshot of the global therapeutic landscape of Relapsing Remitting Multiple Sclerosis (RRMS) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Relapsing Remitting Multiple Sclerosis (RRMS) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Relapsing Remitting Multiple Sclerosis (RRMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Relapsing Remitting Multiple Sclerosis (RRMS) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - MedImmune, LLC - XenoPort, Inc. - Novartis AG - Actelion Ltd - Mitsubishi Tanabe Pharma Corporation - Octapharma AG - Teva Pharmaceutical Industries Limited - Genmab A/S - Merck KGaA - Antisense Therapeutics Limited - Opexa Therapeutics - Trophos SA - Allozyne - Amarna Therapeutics - Synthetic Biologics - Cognosci - RedHill Biopharm - Nuron Biotech - Neurotec Pharma SL - BIOCAD - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/2n69ld/relapsing
GSK: 47.94 (+1.99), XNPT: 6.69 (-0.21), OPXA: 0.71 (-0.03), SYN: 2.13 (+0.18), ABBV: 58.05 (+1.00), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Xenoport, Inc. (XNPT) in Focus: Stock Jumps 5.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 8:21AM CST
Xenoport, Inc. (XNPT) was a big mover last session, as the company saw its shares rise by over 5% on the day.
AFFX: 11.45 (+0.02), XNPT: 6.69 (-0.21)
Stocks Fall in Light Trading as Oil and Greece Weigh on Markets
at The Street - Tue Dec 30, 3:09PM CST
Oil and Greece were the focus of 2014's penultimate trading session in what was an otherwise quiet day.
GPRO: 45.27 (-0.02), HK: 2.18 (-0.02), ABX: 12.14 (+0.01), AKAM: 68.77 (+1.18), FCX: 20.29 (+0.82), NEM: 24.78 (+0.27), XNPT: 6.69 (-0.21), NDRM: 10.76 (+0.22), RDS.A: 66.32 (+0.97), KGC: 2.81 (-0.17), GLD: 117.98 (+0.64), CVEO: 3.87 (+0.15), BP: 41.93 (+0.59), ARCP: 9.40 (+0.06), YELP: 47.53 (-0.10), XLE: 82.04 (+1.70), GG: 23.54 (+0.23)
